Hem CME/CE Courses – Update

Hematology CME/CE Courses

myCME Your search for high-quality, complimentary CME/CE stops right here. The courses below are presented by myCME, the continuing education engine in Haymarket Medical Network’s (HMN) expanding portfolio of clinical websites. Below you’ll find practice-relevant courses that carry valuable CME/CE credit. Simply click any link to get started earning credit on myCME.

Featured Courses

COVID-19 Infections and Hematologic Disturbances

AMA PRA Category 1 Credit(s)^TM

This education will provide physicians with the resources necessary to discuss treatment options with patients, payers and administrators to ensure that each stakeholder understands the importance of those options for the management of patients with hematologic malignancies and COVID-19.

Practical Tools & Expert Guidance for the Nurse Navigator and Clinical Team: Strategies to Reduce Treatment Disparities in Multiple Myeloma

Reduce Treatment Disparities in Multiple Myeloma | myCME

AMA PRA Category 1 Credit(s)^TM

1.00 CME/CE: Real-world strategies using data, guidelines, and decision-making recommendations to ensure the best care for patients with MM. Exp 12/23/22

RME Hot Seat: Weighing the Clinical Evidence on Treatment Strategies for Myeloma

Treatment Strategies for Myeloma | myCME

AMA PRA Category 1 Credit(s)^TM

This RME Hot Seat provides a virtual Q&A with a panel of multiple myeloma (MM) experts who field a range of questions on MM patient care, covering such topics as the use of minimal residual disease (MRD)–driven maintenance approaches, immunotherapy, the use of belantamab mafodotin, cytogenetic risk status, and the value of three-drug and four-drug regimens.

Episode 1: Improving Diagnosis and Risk Stratification of Myelodysplastic Syndrome (MDS)

Episode 1: Improving Diagnosis and Risk Stratification of MDS

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, CNE Contact Hour(s)

This is the first of 3 episodes in this Oncology Prime Time series which will address diagnosis, risk stratification, and the mechanisms and clinical applications of new and emerging agents in MDS.

Episode 2: Relating the Pathophysiology of MDS to the Mechanism of Action (MOA) of Novel Agents

Episode 2: Pathophysiology of MDS and the MOA of Novel Agents

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, CNE Contact Hour(s)

This is the second of 3 episodes in this Oncology Prime Time series which will address diagnosis, risk stratification, and the mechanisms and clinical applications of new and emerging agents in MDS.

Episode 3: Latest Update on Clinical Trial Data of New and Emerging Agents for MDS

Episode 3: Clinical Trial Data of New and Emerging Agents for MDS

AMA PRA Category 1 Credit(s)^TM, CE for Pharmacists, CNE Contact Hour(s)

This is the third of 3 episodes in this Oncology Prime Time series which will address diagnosis, risk stratification, and the mechanisms and clinical applications of new and emerging agents in MDS.

Meeting the Challenges in Management of Sickle Cell Disease | myCME

AMA PRA Category 1 Credit(s)^TM, AANP Contact Hour(s)

Join Michael DeBaun, MD, MPH, and Collin Montgomery, APRN, as they discuss the acute and chronic complications experienced by individuals with sickle cell disease and the barriers they often encounter.

Biosimilars: Implications for Clinical Practice in Hematological Malignancies & Supportive Care | myCME

AMA PRA Category 1 Credit(s)^TM, ANCC Contact Hour(s)

This webcast is intended to improve care of patients with hematological malignancies with biosimilars by accelerating adoption of new guidelines and evidence-based practice change. In-depth discussion of novel agents at various stages of clinical development will be given significant focus. This Internet CME activity is designed to provide clinical decision-making strategies for integration of novel therapeutic options.